Literature DB >> 12668072

High-performance liquid chromatographic assay with fluorescence detection for the simultaneous measurement of carboxylate and lactone forms of irinotecan and three metabolites in human plasma.

Thandranese S Owens1, Helen Dodds, Katrin Fricke, Suzan K Hanna, Kristine R Crews.   

Abstract

Irinotecan (CPT-11), a camptothecin analog, is metabolized to SN-38, an active topoisomerase I inhibitor, and inactive metabolites, including APC and SN-38 glucuronide (SN-38G). A high-performance liquid chromatographic assay method to simultaneously measure the lactone and carboxylate forms of CPT-11, SN-38, SN-38G, and APC in human plasma was developed. Chromatography was accomplished with a reversed-phase C(8) column and fluorescence detection. A gradient mobile phase system was used. The buffer for mobile phase A consisted of 0.75 M ammonium acetate, 5 mM tetrabutylammonium phosphate (pH 6.0), and acetonitrile (86:14, v/v). The buffer for mobile phase B was identical to mobile phase A with the exception of the concentration (50:50, v/v). Precipitation of plasma proteins was performed with cold methanol. The linear range of detection of the lactone and carboxylate forms of SN-38, SN-38G, and APC was 2-25 ng/ml, and 5-300 ng/ml for CPT-11. The limit of quantitation for the analytes ranged from 0.5 to 5 ng/ml. Analysis of patients' plasma samples obtained before and after CPT-11 administration showed that the assay is suitable for measuring lactone and carboxylate forms of CPT-11, SN-38, SN-38G, and APC in clinical studies.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12668072     DOI: 10.1016/s1570-0232(02)01016-4

Source DB:  PubMed          Journal:  J Chromatogr B Analyt Technol Biomed Life Sci        ISSN: 1570-0232            Impact factor:   3.205


  7 in total

1.  Quantification of irinotecan, SN38, and SN38G in human and porcine plasma by ultra high-performance liquid chromatography-tandem mass spectrometry and its application to hepatic chemoembolization.

Authors:  Xiaohong Chen; Cody J Peer; Raul Alfaro; Tian Tian; Shawn D Spencer; William D Figg
Journal:  J Pharm Biomed Anal       Date:  2012-01-16       Impact factor: 3.935

2.  Phase I study of vincristine, irinotecan, and ¹³¹I-metaiodobenzylguanidine for patients with relapsed or refractory neuroblastoma: a new approaches to neuroblastoma therapy trial.

Authors:  Steven G DuBois; Louis Chesler; Susan Groshen; Randall Hawkins; Fariba Goodarzian; Hiroyuki Shimada; Greg Yanik; Michael Tagen; Clinton Stewart; Yael P Mosse; John M Maris; Denice Tsao-Wei; Araz Marachelian; Judith G Villablanca; Katherine K Matthay
Journal:  Clin Cancer Res       Date:  2012-03-15       Impact factor: 12.531

3.  Phase I dose escalation and pharmacokinetic study of oral gefitinib and irinotecan in children with refractory solid tumors.

Authors:  R C Brennan; W Furman; S Mao; J Wu; D C Turner; C F Stewart; V Santana; L M McGregor
Journal:  Cancer Chemother Pharmacol       Date:  2014-09-26       Impact factor: 3.333

4.  A single-arm pilot phase II study of gefitinib and irinotecan in children with newly diagnosed high-risk neuroblastoma.

Authors:  Wayne L Furman; Lisa M McGregor; M Beth McCarville; Mihaela Onciu; Andrew M Davidoff; Sandy Kovach; Dana Hawkins; Valerie McPherson; Peter J Houghton; Catherine A Billups; Jianrong Wu; Clinton F Stewart; Victor M Santana
Journal:  Invest New Drugs       Date:  2011-07-28       Impact factor: 3.850

5.  Phase I trial of oral irinotecan and temozolomide for children with relapsed high-risk neuroblastoma: a new approach to neuroblastoma therapy consortium study.

Authors:  Lars M Wagner; Judith G Villablanca; Clinton F Stewart; Kristine R Crews; Susan Groshen; C Patrick Reynolds; Julie R Park; John M Maris; Randall A Hawkins; Heike E Daldrup-Link; Hollie A Jackson; Katherine K Matthay
Journal:  J Clin Oncol       Date:  2009-01-26       Impact factor: 44.544

6.  Tyrosine kinase inhibitor enhances the bioavailability of oral irinotecan in pediatric patients with refractory solid tumors.

Authors:  Wayne L Furman; Fariba Navid; Najat C Daw; M Beth McCarville; Lisa M McGregor; Sheri L Spunt; Carlos Rodriguez-Galindo; John C Panetta; Kristine R Crews; Jianrong Wu; Amar J Gajjar; Peter J Houghton; Victor M Santana; Clinton F Stewart
Journal:  J Clin Oncol       Date:  2009-08-17       Impact factor: 44.544

7.  Development and validation of a high-performance liquid chromatography-tandem mass spectrometry method for the simultaneous determination of irinotecan and its main metabolites in human plasma and its application in a clinical pharmacokinetic study.

Authors:  Elena Marangon; Bianca Posocco; Elisa Mazzega; Giuseppe Toffoli
Journal:  PLoS One       Date:  2015-02-17       Impact factor: 3.240

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.